A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

The Study will also include use of certain glucagon-like peptide-1 ("GLP-1") receptor specific antibodies detectable ... Such forward-looking statements are estimates reflecting the Company's best ...

More than 48 million Americans 12 years or older had a substance use disorder in 2022, yet only 24 percent received treatment ...

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

Good afternoon, and welcome to Fractyl Health's Third Quarter Financial Results and Business Updates Call. As a reminder, this conference call is being recorded. [Operator Instructions]. I will now ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Over the past three decades, there has been a startling increase in the prevalence of obesity across the U.S., at least ...

DaVita’s strong services face risks from debt and economic uncertainties. Find out why DVA stock is a "Hold" with a $130 ...

YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3– TransCon CNP ...

Everyone is raving about the slimming power of semaglutide medications like Ozempic and Wegovy, which experts say is as ...